CompletedPhase 2

Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau

United States15 participantsStarted 2019-09-23

Plain-language summary

The purpose of this study is to determine if contrast-enhanced ultrasound can detect abnormal features of kidney lesions in patients with Von-Hippel Lindau with the same accuracy as conventional ultrasound and contrast-enhanced magnetic resonance imaging (MRI)

Who can participate

Age range16 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Able to provide written informed consent
✓. Willing to comply with protocol requirements
✓. At least 16 years of age
✓. Carry a diagnosis of VHL and able to undergo routine clinical screening tests for RCC

Exclusion criteria

✕. Critically ill or medically unstable or in an intensive care setting and whose critical course during the observation period would be unpredictable
✕. Known hypersensitivity to sulfur hexafluoride or to any component of perflutren lipid (Definity®) or sulfur hexafluoride (Lumason®)
✕. Right to left shunt, severe pulmonary hypertension (Pulmonary artery pressure \>90mmHg), or adult respiratory distress syndrome
✕. Active cardiac disease including any of the following:
✕. Has any other medical condition or other circumstances that would significantly decrease the chances of obtaining reliable data or of achieving the study objectives such as:
✕. Female patient who is pregnant or lactating
✕. Obesity that limits obtainment of acceptable images

What they're measuring

Comparison in Radiologist's Lesion Evaluation: CEUS Versus B-mode Ultrasound

Timeframe: Baseline

Trial details

NCT IDNCT03907657

SponsorUNC Lineberger Comprehensive Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-03-13

Results submitted2024-02-27

View on ClinicalTrials.gov More Von-Hippel Lindau trials